Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer Meeting Abstract


Authors: Janjigian, Y. Y.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Siebel, M.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; Kelsen, D. P.; Imtiaz, T.; Ilson, D. H.
Abstract Title: Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036900892
PROVIDER: wos
Notes: Meeting Abstract: 4053 -- Source: Wos
MSK Authors
  1. Joanne Fu-Lou Chou
    149 Chou
  2. Michelle S Boyar
    3 Boyar
  3. Geoffrey Yuyat Ku
    82 Ku
  4. Marinela Capanu
    194 Capanu
  5. Yelena Yuriy Janjigian
    138 Janjigian
  6. David H Ilson
    259 Ilson
  7. David P Kelsen
    316 Kelsen
  8. Tooba   Imtiaz
    7 Imtiaz
  9. Marisa Faye Siebel
    1 Siebel
  10. Avni Mukund Desai
    5 Desai